Form 10-Q Revance Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St ends mixed as oil takes a pause
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
William Blair Reviews Revance Therapeutic (RVNC) EPS
May 13, 2024 7:04 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Revance Therapeutic (NASDAQ: RVNC).
The analyst comments "Revance announced first quarter 2024 DAXXIFY revenues of $22.1 million, approximating our estimate of $22.2 million and just shy of consensus of $23.5 million. While the first quarter is typically... More
